Larin 24 Fe 1/20 Shortage: What Providers and Prescribers Need to Know in 2026

Patients on Larin 24 Fe 1/20 may contact your practice asking for help when their pharmacy can't fill their prescription. While there is no formal FDA shortage of this combination oral contraceptive as of 2026, localized stockouts and formulary-driven availability issues require providers to have a clear, efficient workflow for managing these situations.

This guide covers the clinical essentials: what Larin 24 Fe is, why it may be unavailable, which substitutions are appropriate, and how to communicate effectively with patients.

Clinical Overview of Larin 24 Fe 1/20

Larin 24 Fe 1/20 is a combination hormonal contraceptive (CHC) manufactured by Northstar Rx LLC. It contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol as active ingredients, dispensed in a 24+4 regimen (24 active tablets, 4 non-hormonal ferrous fumarate placebo tablets per pack).

The 24-day active regimen was developed to reduce the hormone-free interval compared to traditional 21-day regimens, resulting in a shorter, lighter withdrawal bleed and reduced cycle-related symptoms for many patients. The Pearl Index in clinical trials was 1.82 (95% CI 0.59–4.25) among women aged 18–45.

The mechanism of action, as with all CHCs, is primarily suppression of gonadotropin-mediated ovulation. Secondary mechanisms include cervical mucus thickening (reducing sperm penetration) and endometrial atrophy (reducing implantation probability).

Why Patients Are Reporting Difficulty Filling Larin 24 Fe in 2026

Larin 24 Fe is not on the FDA Drug Shortage Database as of 2026. However, clinicians should understand several structural factors that drive localized unavailability:

Brand proliferation and pharmacy stocking decisions: Pharmacies contract with specific distributors and typically stock one or two preferred brands of any given formulation. Patients prescribed Larin 24 Fe specifically may find their pharmacy stocks a different brand in the same class.

Formulary churn: Insurance formulary updates at the start of plan years can redirect patient demand to specific brands, temporarily straining supply of others.

Production variability: Even without an FDA-designated shortage, individual manufacturers can experience batch delays or capacity constraints that affect regional availability.

Therapeutic Substitution: Appropriate Alternatives

The following products are direct therapeutic equivalents, containing identical active ingredients on the same schedule. They are interchangeable from a pharmacological standpoint:

Junel 24 Fe (norethindrone acetate 1 mg / EE 20 mcg, 24+4) — Glenmark

Blisovi 24 Fe (norethindrone acetate 1 mg / EE 20 mcg, 24+4) — Amneal

Hailey 24 Fe (norethindrone acetate 1 mg / EE 20 mcg, 24+4) — Breckenridge

Microgestin 24 Fe (norethindrone acetate 1 mg / EE 20 mcg, 24+4) — Watson/Allergan

Tarina 24 Fe / Aurovela 24 Fe (same formulation, additional manufacturers)

When writing prescriptions, consider using the generic name ("norethindrone acetate 1 mg / ethinyl estradiol 20 mcg 24+4 tablets") rather than the brand name, or explicitly noting "may substitute equivalent generic" to give the pharmacist flexibility.

Prescribing Notes: When a Direct Substitute Is Not Appropriate

In most cases, switching between equivalent 24+4 norethindrone acetate/EE formulations is uncomplicated. However, consider these situations where additional clinical judgment is warranted:

Patient is also on lamotrigine: COC initiation or brand changes can alter lamotrigine plasma levels. Coordinate with the patient's neurologist before making any COC changes.

Patient is on enzyme-inducing medications (rifampin, carbamazepine, topiramate, St. John's Wort): These drugs reduce COC efficacy regardless of brand; switching brands won't mitigate this interaction.

Patient is using Larin 24 Fe for acne management: Some norethindrone-based COCs are not FDA-approved specifically for acne. If acne treatment is a priority, Yaz, Ortho Tri-Cyclen, Estrostep Fe, or Beyaz may be more appropriate alternatives.

Communicating With Patients About Larin 24 Fe Availability

Patients often become anxious when they can't fill their birth control prescription. Clear, proactive communication reduces unnecessary worry and helps them take action quickly:

Reassure patients that equivalent alternatives are available and equally effective.

Advise them to call multiple pharmacies or use medfinder.com to locate stock without extended phone time.

Offer to send a new prescription for an equivalent to a pharmacy that has it in stock — this can usually be done through your EHR's e-prescribing tool in under two minutes.

For patients switching mid-pack: they can start the new equivalent brand the next day (continuing in sequence), with no loss of contraceptive protection for same-dose equivalents.

Helping Your Practice Reduce Prescription Friction

medfinder for providers offers a streamlined way to help patients navigate pharmacy availability. Providers can recommend medfinder.com/providers to their patients, reducing the volume of "my pharmacy doesn't have it" callbacks to your practice. medfinder contacts pharmacies on the patient's behalf and texts them results — putting the patient in control of finding their medication.

For a provider-focused resource to share with colleagues, see our companion article: How to Help Your Patients Find Larin 24 Fe in Stock.